Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 3
2002 1
2003 2
2004 6
2005 6
2006 15
2007 12
2008 12
2009 35
2010 40
2011 40
2012 44
2013 39
2014 36
2015 24
2016 21
2017 12
2018 8
2019 4
2020 3
2021 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

317 results
Results by year
Filters applied: . Clear all
Page 1
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Oparil S, et al. J Clin Hypertens (Greenwich). 2001 Sep-Oct;3(5):283-91, 318. doi: 10.1111/j.1524-6175.2001.01136.x. J Clin Hypertens (Greenwich). 2001. PMID: 11588406 Free PMC article. Clinical Trial.
The reduction in mean 24-hour SBP with olmesartan (12.5 mm Hg) was significantly greater than the reductions with losartan and valsartan (9.0 and 8.1 mm Hg, respectively) and equivalent to the reduction with irbesartan (11.3 mm Hg). All drugs were well tolerated. The autho …
The reduction in mean 24-hour SBP with olmesartan (12.5 mm Hg) was significantly greater than the reductions with losartan and valsar …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. ...The safety and tolerability profiles of sacubitril/valsarta

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Huo Y, et al. J Clin Hypertens (Greenwich). 2019 Jan;21(1):67-76. doi: 10.1111/jch.13437. Epub 2018 Dec 11. J Clin Hypertens (Greenwich). 2019. PMID: 30536595 Free PMC article. Clinical Trial.
The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olmesartan 20 mg at Week 8. Secondary endpoints included msSBP reduction with sacubitril/valsartan 400 mg, and reductions in clinic and ambu …
The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olme
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, Hrabak-Paar M, Heye T, Aichner S, Khder Y, Yates D, Albrecht D, Langenickel T, Freyhardt P, Janka R, Bremerich J. Schmieder RE, et al. Eur Heart J. 2017 Nov 21;38(44):3308-3317. doi: 10.1093/eurheartj/ehx525. Eur Heart J. 2017. PMID: 29029087 Clinical Trial.
Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from baseline to 12 weeks (-6.36 vs. -2.32 g/m2; P = 0.039) and from baseline to 52 weeks (-6.83 vs. -3.55 g/m2; P = 0.029). ...There were no signif …
Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from bas …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, …
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were random …
Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods.
Iseki K, Tokuyama K, Shiohira Y, Higa A, Hirano H, Toma S, Kohagura K, Ueda S. Iseki K, et al. Clin Exp Nephrol. 2009 Apr;13(2):145-151. doi: 10.1007/s10157-008-0116-8. Epub 2008 Dec 20. Clin Exp Nephrol. 2009. PMID: 19101780 Clinical Trial.
The outcomes will be compared between two treatment regimens, such as (1) renin-angiotensin system (RAS) inhibitor Olmesartan and others, and (2) antihypertensive drugs without RAS inhibitors, in a parallel fashion. The title of the study is Olmesartan Clinical Tria …
The outcomes will be compared between two treatment regimens, such as (1) renin-angiotensin system (RAS) inhibitor Olmesartan and oth …
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P. Derosa G, et al. Eur J Pharm Sci. 2014 Jan 23;51:26-33. doi: 10.1016/j.ejps.2013.08.031. Epub 2013 Aug 30. Eur J Pharm Sci. 2014. PMID: 23999037 Retracted. Clinical Trial.
Olmesartan/amlodipine combination better decreased FPI and HOMA index and increased M value compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased chemerin and omentin compared to olmesartan and amlodipine. .
Olmesartan/amlodipine combination better decreased FPI and HOMA index and increased M value compared to olmesartan and amlodip
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice.
Bramlage P, Wolf WP, Stuhr T, Fronk EM, Erdlenbruch W, Ketelhut R, Schmieder RE. Bramlage P, et al. Vasc Health Risk Manag. 2010 Sep 7;6:803-11. doi: 10.2147/vhrm.s13441. Vasc Health Risk Manag. 2010. PMID: 20859549 Free PMC article. Clinical Trial.
OBJECTIVES: To assess the efficacy and tolerability of a fixed-dose combination of olmesartan and amlodipine in an unselected population of patients in primary care and to compare the results with recent randomized controlled trial evidence. ...RESULTS: Patients had a mean …
OBJECTIVES: To assess the efficacy and tolerability of a fixed-dose combination of olmesartan and amlodipine in an unselected populat …
Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension.
Shiga Y, Miura SI, Motozato K, Norimatsu K, Yano M, Hitaka Y, Adachi S, Kuwano T, Inoue K, Inoue A, Fujisawa K, Shirotani T, Kusumoto T, Ideishi M, Saku K. Shiga Y, et al. Int Heart J. 2017 May 31;58(3):416-421. doi: 10.1536/ihj.16-285. Epub 2017 May 12. Int Heart J. 2017. PMID: 28496022 Free article. Clinical Trial.
We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hypertensive patients who were treated with ARBs other than azilsartan and olmesartan were enrolled in this study. ...In conclusion, there …
We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hyper …
Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Arao T, Okada Y, Mori H, Nishida K, Tanaka Y. Arao T, et al. Endocr J. 2013;60(5):563-70. doi: 10.1507/endocrj.ej12-0326. Epub 2013 Jan 10. Endocr J. 2013. PMID: 23303198 Free article. Clinical Trial.
There were 1) no significant differences in baseline characteristics; 2) no significant difference of the blood pressure reduction rate; 3) significant reductions of HbA1c (NGSP), FPG and HOMA-IR in olmesartan group; 4) a significant increase of HDL-C in olmesartan
There were 1) no significant differences in baseline characteristics; 2) no significant difference of the blood pressure reduction rate; 3) …
317 results